“Our high success rate with evaluating challenging POC samples includes both fresh and formalin-fixed, paraffin-embedded samples, thus providing significant advantages and options to clinicians and providers. Further, the ability of single nucleotide polymorphism-based microarray analysis to identify aneuploidy, polyploidy, whole-genome homozygosity, segmental genomic imbalances and maternal cell contamination maximizes sensitivity and decreases the number of false-negative results,” commented study author Dr. Trilochan Sahoo, CombiMatrix’s vice president of clinical affairs and director of cytogenetics.